¶ fatty acid
¶ Definition
Organic molecules consisting of a hydrocarbon chain with a terminal carboxyl group (-COOH), classified by chain length (short, medium, long, very long) and saturation status (saturated, monounsaturated, polyunsaturated). Fatty acids serve three critical roles in cPNI: energy substrates via beta-oxidation, structural components determining cell membranes fluidity and receptor function, and precursors to bioactive lipid mediators including both pro-inflammatory eicosanoids and anti-inflammatory Specialized pro-resolving mediators (SPMs). The omega-6/omega-3 ratio is the single most important nutritional determinant of inflammatory tone.
¶ Picture It
Think of fatty acids as raw lumber arriving at a construction site. The building foreman (your cell) can do three things with the wood: burn it in the furnace for heat (beta-oxidation for energy), use it to build the walls of the building (cell membranes), or send it to the workshop where specialized carpenters (COX-2, 15-LOX, Cytochrome P450) transform it into specific tools—either sledgehammers and crowbars (pro-inflammatory eicosanoids from omega-6 fatty acids like arachidonic acid) or precision repair kits and cleanup crews (Resolvins and Maresins from omega-3 fatty acids like EPA and DHA).
The type of lumber you deliver determines what tools get made. If you deliver 15-20 truckloads of omega-6 lumber for every 1 truckload of omega-3 (the modern Western diet ratio), you'll end up with warehouses full of demolition tools and almost no repair kits. The construction site becomes permanently stuck in demolition mode (chronic inflammation) because nobody ordered enough omega-3 lumber to make the cleanup tools needed to finish the job (resolution). The evolutionary ratio was 1-4:1, meaning roughly equal amounts of demolition and repair tools—a balanced worksite.
¶ Mechanism
Fatty acids undergo three distinct metabolic fates depending on cellular energy state and signaling context:
Energy Metabolism Pathway:
Fatty acids enter mitochondria via carnitine shuttle (CPT1A) → beta-oxidation cleaves 2-carbon acetyl-CoA units → acetyl-CoA enters Krebs cycle → electron transport chain generates ~105-129 ATP per 16-carbon palmitate → produces 3× more ATP per gram than glucose, making fat the preferred fuel during Intermittent fasting or prolonged exercise
Membrane Incorporation:
Dietary fatty acids → absorbed as micelles in small intestine → re-esterified into triglycerides in enterocytes → packaged into chylomicrons → delivered to tissues → phospholipase A2 (PLA2) cleaves fatty acids from membrane phospholipids when needed → fatty acid composition determines membrane fluidity (saturated = rigid, polyunsaturated = fluid) → affects receptor conformation, ion channel function, and lipid raft formation
Lipid Mediator Biosynthesis (the critical cPNI pathway):
Omega-6 Cascade (Pro-inflammatory Dominance):
Linoleic acid (18:2n-6) → delta-6 desaturase → gamma-linolenic acid → elongase → arachidonic acid (20:4n-6) stored in membrane → cellular activation (stress, cytokines, injury) → cytosolic phospholipase A2 (cPLA2) → free arachidonic acid →
Branch 1: COX-2 → Prostaglandins (PGE2, PGI2) + thromboxanes (TXA2) → vasodilation, pain sensitization, platelet aggregation, fever via hypothalamus PGE2 receptors
Branch 2: 5-LOX → 5-HPETE → leukotrienes (LTB4, LTC4, LTD4, LTE4) → neutrophil chemotaxis, vascular permeability, bronchoconstriction
Branch 3: 12-LOX → 12-HETE → platelet activation
Omega-3 Cascade (Resolution Dominance):
EPA (20:5n-3) and DHA (22:6n-3) → same PLA2 release → compete for same enzymes but produce different products →
EPA via COX-2 → 3-series Prostaglandins (PGE3, less inflammatory than PGE2)
EPA via 5-LOX → 5-series leukotrienes (LTB5, 10-100× less potent than LTB4)
Aspirin modification creates resolution mediators:
COX-2 + aspirin acetylation → COX-2 produces 15R-HETE from arachidonic acid instead of PGE2 → 15-epi-lipoxin A4 (aspirin-triggered lipoxin, ATL) → resolution signal
DHA/EPA via specialized enzymes produce SPMs:
DHA + 15-LOX → 17-HDHA → Resolvins D-series (RvD1-6) binding to ALX-FPR2 receptor and GPR32 → stops neutrophil infiltration, enhances macrophage efferocytosis, reduces pain via TRPV1 modulation
EPA + 5-LOX → 18-HEPE → Resolvins E-series (RvE1-3) → anti-inflammatory, pro-resolution
DHA + 12-LOX → 14-HDHA → Maresins (MaR1, MaR2) → tissue regeneration, macrophage reprogramming to M2 phenotype
Saturated Fatty Acid Inflammatory Pathway:
Saturated Fatty Acids (palmitate, stearate) → direct binding to TLR4 (mimicking LPS) → MyD88 → NF-kB activation → IL-6, TNF-α, IL-1β production → insulin resistance via serine phosphorylation of Insulin receptor substrate-1 (IRS-1) blocking insulin signaling
Threshold Effects:
- Delta-6 desaturase activity: rate-limiting step for both omega-6 and omega-3 conversion, impaired by: high insulin, trans fats, alcohol, aging, zinc/magnesium deficiency
- Competitive inhibition: EPA/DHA at >2g/day can displace arachidonic acid from membrane phospholipids, reducing substrate availability for pro-inflammatory eicosanoid synthesis
- COX-2 affinity: 10× higher for arachidonic acid than EPA, explaining why high omega-6 intake drives inflammatory mediator production even with adequate omega-3
¶ Clinical Significance
Primary Clinical Application—Inflammatory Pain Syndromes:
Neuropathic pain responds dramatically to DHA supplementation at 6 grams daily via correction of lipid mediator imbalance. Mechanism: high-dose DHA → membrane incorporation → increased RvD1, RvD2 production → TRPV1 desensitization on nociceptors → reduced peripheral sensitization → decreased Substance P and CGRP release from dorsal root ganglia. Clinical studies show 30-50% pain reduction within 4-6 weeks at this dose. This intervention addresses chronic inflammation and failed resolution simultaneously—a core cPNI principle.
Evolutionary Mismatch Context:
The modern omega-6/omega-3 ratio of 15-20:1 (vs ancestral 1-4:1) represents one of the most profound nutritional mismatches in human history. Agricultural revolution introduced seed oils (corn, soybean, sunflower—all omega-6 dominant) while eliminating wild game, fish, and plant sources rich in omega-3. This ratio shift creates constitutive low-grade metaflammation because cells are constantly building pro-inflammatory mediators from available substrate. The selfish immune system interprets this as chronic threat, maintaining defensive posture that impairs metabolism, neuroplasticity, and gut barrier function.
Metamodel Integration:
- Metamodel 1 (Lifestyle): Dietary fatty acid composition is THE modifiable driver of inflammatory tone—more impactful than most pharmaceutical interventions
- Metamodel 2 (Stress): Cortisol activates phospholipase A2, releasing arachidonic acid; chronic stress + high omega-6 diet = inflammatory amplification
- Metamodel 3 (Gut): Gut dysbiosis produces inflammatory oxylipins from dietary linoleic acid; leaky gut allows bacterial lipopolysaccharide to synergize with dietary Saturated Fatty Acids at TLR4
- Metamodel 5 (Toxicity): AGEs (advanced glycation end-products) and oxidized linoleic acid metabolites (OXLAMs) create self-perpetuating inflammatory loops
Condition-Specific Applications:
Insulin resistance/Type 2 Diabetes: Saturated Fatty Acids activate TLR4 → IKK → serine phosphorylation of IRS-1 → blocked Insulin signaling. Intervention: replace saturated fat with omega-3, increase membrane fluidity to restore insulin receptor function.
Depression: Low DHA correlates with reduced BDNF, increased IL-6, impaired neuroplasticity. DHA 2-4g daily improves treatment-resistant depression via Resolvins reducing neuroinflammation and direct membrane effects on serotonergic neuron function.
Autoimmunity (RA, MS, IBD): High omega-6 perpetuates Th1/Th17 polarization; EPA/DHA shift toward Treg cells via RvD1 and RvE1 binding to immune cell receptors. Clinical threshold: omega-3 index (RBC membrane EPA+DHA) >8% associated with remission in rheumatoid arthritis.
Cardiovascular disease: Resolvins stabilize atherosclerotic plaques, reduce endothelial activation, prevent thrombosis. EPA 4g daily (REDUCE-IT trial) showed 25% reduction in cardiovascular events via resolution pathway activation, NOT just lipid lowering.
Biomarker Targets:
- Omega-6/omega-3 ratio: aim for <4:1 (measured via RBC fatty acid profile)
- Omega-3 index: target >8% (cardioprotective, anti-inflammatory)
- AA/EPA ratio:
:1 optimal for resolution capacity - CRP: high omega-6 diets maintain CRP >3 mg/L; omega-3 supplementation reduces to <1 mg/L
Clinical Protocol Considerations:
High-dose omega-3 (>4g/day) requires: baseline lipid panel, monitor for bleeding risk in patients on anticoagulants, use triglyceride form (better absorbed than ethyl ester), take with fat-containing meals, store refrigerated to prevent oxidation. Contraindicated in aspirin-sensitive patients due to COX-2 interaction producing aspirin-triggered resolvins.
¶ Key Facts
- Evolutionary omega-6/omega-3 ratio was 1-4:1; modern Western diet is 15-20:1, creating constitutive pro-inflammatory mediator dominance
- DHA at 6 grams daily reduces neuropathic pain by 30-50% within 4-6 weeks via RvD1/RvD2 production and TRPV1 desensitization
- Saturated fatty acids activate TLR4 at concentrations >200 μM, mimicking bacterial LPS and triggering NF-kB-mediated inflammation
- Delta-6 desaturase is rate-limiting for both omega-6 and omega-3 elongation; impaired by high insulin, trans fats, aging, and zinc deficiency
- EPA/DHA at >2g/day displace arachidonic acid from membrane phospholipids, reducing substrate for pro-inflammatory eicosanoids
- COX-2 has 10× higher affinity for arachidonic acid than EPA, explaining inflammatory dominance even with moderate omega-3 intake
- Omega-3 index (RBC EPA+DHA) >8% is cardioprotective and anti-inflammatory; <4% associated with increased all-cause mortality
- LTB4 (from arachidonic acid) is 10-100× more potent than LTB5 (from EPA) for neutrophil chemotaxis
- Aspirin acetylates COX-2 at Ser-530, switching it from PGE2 production to 15-epi-lipoxin synthesis (aspirin-triggered resolution)
- Medium-chain triglycerides (C8-C12) bypass carnitine shuttle, entering mitochondria directly for rapid ketone production during fasting
- DHA comprises 40% of brain phospholipid fatty acids and 60% of retinal photoreceptor membranes, explaining neurocognitive effects of deficiency
- RvD1 binds ALX-FPR2 receptor with Kd = 0.2 nM, making it one of the most potent anti-inflammatory lipid mediators known
¶ Connections
- DHA — omega-3 fatty acid producing D-series Resolvins and Neuroprotectins; 6g/day treats neuropathic pain via TRPV1 modulation
- EPA — omega-3 producing E-series Resolvins and less inflammatory 3-series Prostaglandins; 4g/day reduces cardiovascular events
- omega-3 — collective term for anti-inflammatory fatty acid family; membrane incorporation competitively inhibits arachidonic acid metabolism
- omega-6 — predominantly pro-inflammatory fatty acid family; linoleic acid from seed oils drives modern inflammatory disease burden
- linoleic acid — 18:2n-6, most abundant dietary omega-6; converted to arachidonic acid then pro-inflammatory eicosanoids and leukotrienes
- arachidonic acid — 20:4n-6, direct substrate for COX-2, 5-LOX, 12-LOX producing inflammatory mediators; displaced from membranes by high-dose omega-3
- Specialized pro-resolving mediators (SPMs) — Resolvins, Maresins, Protectins derived from EPA/DHA; actively terminate inflammation and promote tissue repair
- Resolvins — resolution-phase lipid mediators binding ALX-FPR2 and GPR32; D-series from DHA, E-series from EPA
- Maresins — DHA-derived mediators via 12-LOX; promote macrophage efferocytosis and M2 polarization during resolution
- Protectins — DHA-derived neuroprotective mediators; NPD1 in brain reduces neuroinflammation and promotes neuroplasticity
- COX-2 — inducible enzyme converting arachidonic acid to PGE2/PGI2; aspirin acetylation switches to resolvin precursor synthesis
- 15-LOX — lipoxygenase producing Resolvins and Protectins from EPA/DHA; key resolution pathway enzyme
- 5-LOX — generates LTB4 from arachidonic acid (neutrophil recruitment) or resolvin precursors from EPA
- 12-LOX — produces Maresins from DHA and 12-HETE from arachidonic acid
- Cytochrome P450 — CYP enzymes produce specialized epoxy-metabolites from fatty acids; CYP2J/2C generate anti-inflammatory EETs
- eicosanoids — 20-carbon lipid mediators from arachidonic acid; include Prostaglandins, leukotrienes, thromboxanes
- Prostaglandins — COX products causing vasodilation, pain, fever; PGE2 from omega-6 vs less inflammatory PGE3 from omega-3
- leukotrienes — 5-LOX products; LTB4 from arachidonic acid causes neutrophil chemotaxis and vascular permeability
- beta-oxidation — mitochondrial fatty acid catabolism producing acetyl-CoA and ATP; impaired in insulin resistance and mitochondrial dysfunction
- TLR4 — pattern recognition receptor activated by Saturated Fatty Acids (palmitate) mimicking LPS, triggering NF-kB inflammation
- cell membranes — phospholipid bilayer composition determines fluidity, receptor function, raft formation; altered by dietary fatty acid profile
- neuropathic pain — responds to high-dose DHA 6g/day via resolvin-mediated desensitization of TRPV1 channels on nociceptors
- chronic inflammation — perpetuated by excessive omega-6/omega-3 ratio preventing transition from inflammatory to resolution phase
- insulin resistance — caused by Saturated Fatty Acids activating TLR4 → IKK → serine phosphorylation blocking Insulin receptor signaling
- neuroinflammation — reduced by DHA-derived Protectins and Resolvins acting on microglial activation and BBB integrity
- gut microbiome — produces inflammatory oxylipins from dietary linoleic acid; Short-chain fatty acids from fiber fermentation oppose this
- inflammation — initiated and resolved by different fatty acid-derived mediators; omega-6/omega-3 ratio determines balance
- resolution — active process requiring SPM production from omega-3; impaired when omega-6 dominates substrate availability
- ketones — beta-hydroxybutyrate produced from fatty acid beta-oxidation during Intermittent fasting; anti-inflammatory NLRP3 inhibitor
- Depression — low DHA impairs BDNF, increases IL-6; supplementation 2-4g daily improves treatment-resistant cases
- rheumatoid arthritis — omega-3 index >8% correlates with remission via Treg cells promotion and reduced IL-1β/TNF-α
- atherosclerosis — Resolvins stabilize plaques, reduce endothelial activation; EPA 4g/day reduces cardiovascular events 25%
- microglial activation — driven by omega-6 eicosanoids; suppressed by DHA-derived Resolvins reducing neuroinflammation
¶ Module References
- Module 1 (Introduction)
- Module 2 (Wound Healing, Immune System, Organs)
- Module 10 (Nutrition, Clinical Applications)